Larvol Delta - Akamis-Bio-Announces-Publication-Detailing-Initial-Proof-of-Mechanism-for-NG350A-an-IVDosed-Tumor-Gene-Therapy-Delivering-a-CD40-Agonist-Payload

NG-350A - Akamis Bio

https://www.businesswire.com/news/home/20241023939308/en/Akamis-Bio-Announces-Publication-Detailing-Initial-Proof-of-Mechanism-for-NG-350A-an-IV-Dosed-Tumor-Gene-Therapy-Delivering-a-CD40-Agonist-Payload

Oct 23, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next